USA flag logo/image

An Official Website of the United States Government

A microfluidic chemotaxis device for high content screening

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85824
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HL088785
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BELLBROOK LABS, LLC
5500 NOBEL DR, STE 230 MADISON, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: A microfluidic chemotaxis device for high content screening
Agency: HHS
Contract: 2R44HL088785-02
Award Amount: $963,340.00
 

Abstract:

DESCRIPTION (provided by applicant): Leukocyte recruitment is central to inflammation, and there is intense focus on inhibiting the process both for chronic inflammatory disorders and for conditions where inflammation plays a contributory role, such as ath erosclerosis. Whereas current anti-inflammatory drugs such as NSAIDs target secondary effects that are induced after inflammation is already established, inhibiting leukocyte recruitment would prevent the initiation of inappropriate inflammatory responses. Chemotaxis - the movement of cells aligned with a chemical gradient - is the fundamental process underlying neutrophil recruitment. Despite its importance, there are limited screening tools available for medium to high throughput analysis of leukocyte rec ruitment. Typically, primary screening incorporates a molecular target such as an enzyme or receptor, and hits are then validated in cumbersome in vitro cell migration assays. Existing assays suffer from three main problems: 1) Lack of repeatability (e.g. due to trapped air), 2) need for manual operations (e.g. filter removal), and 3) large cell number requirement (e.g. 1x105 cells/datum). We aim to solve each of these problems by taking advantage of microfluidic technology. In this phase II project we will establish injection molding of full plate (i.e. 96 unit) parts and adapt manufacturing methods developed under the phase I grant to produce devices that suitable for automation. We will use these devices to show reproducibility and data quality while redu cing the number of cells required per datum 10-fold. Importantly we will demonstrate the use of the microfluidic chemotaxis device in a high content screening study where multi-parametric image- based analysis is applied to test both migration and polariza tion of primary human neutrophils. PUBLIC HEALTH RELEVANCE: The migration of cells from the bloodstream to sites of injury is one of the fundamental processes underlying chronic inflammatory disorders such as arthritis and inflammatory bowel disease. Respo nding cells migrate toward higher concentrations of signaling molecules that are released at the injury site. To enable the discovery of drugs to block this process, we are developing plastic devices for high throughput cell migration assays in defined che mical gradients.

Principal Investigator:

Ivar Meyvantsson
6082274517
IVAR.MEYVANTSSON@BELLBROOKLABS.COM

Business Contact:

Robert G. Lowery
bob.lowery@bellbrooklabs.com
Small Business Information at Submission:

BELLBROOK LABS, LLC
5500 Nobel Drive Suite 250 MADISON, WI 53711

EIN/Tax ID: 043661356
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No